Enasidenib

Contraindicated

Enasidenib Colchicine Colcrys Increased colchicine exposure, an increased risk of colchicine toxicity, reduced colchicine and reduced efficacy of colchicine Details Enasidenib Agomelatine Increased agomelatine exposure Details Enasidenib Bacillus Of Calmette And Guerin Vaccine, Live An increased risk of infection by the live vaccine Details Enasidenib Dengue Tetravalent Vaccine, Live An increased risk of infection by the live vaccine Details Enasidenib Elagolix Orilissa Increased elagolix exposure and an increased risk of elagolix-related adverse reactions Details Enasidenib Fezolinetant Increased fezolinetant exposure Details Enasidenib Grazoprevir Increased grazoprevir exposure and an increased risk of ALT elevation Details Enasidenib Measles Virus Vaccine, Live An increased risk of infection by the live vaccine Details Enasidenib Mumps Virus Vaccine, Live An increased risk of infection by the live vaccine Details Enasidenib Ranolazine Aspruzyo Increased or reduced ranolazine exposure Details Enasidenib Rubella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Enasidenib Smallpox Monkeypox Vaccine An increased risk of infection by the live vaccine Details Enasidenib Tizanidine Increased tiZANidine exposure and an increased risk of tiZANidine-related hypotension, an increased drowsiness and psychomotor imp... Details Enasidenib Typhoid Vaccine Typhim VI® An increased risk of infection by the live vaccine Details Enasidenib Varicella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Enasidenib Yellow Fever Vaccine Stamaril An increased risk of infection by the live vaccine Details

Major

Enasidenib Clindamycin ANTIROBE Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Enasidenib Relugolix Orgovyx Increased relugolix exposure Details Enasidenib Abemaciclib Verzenio Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Enasidenib Acalabrutinib Calquence Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Enasidenib Alpelisib Piqray Increased alpelisib exposure and an increased risk of alpelisib-related adverse effects and toxicity Details Enasidenib Asenapine Transdermal Patch Secuado Increased asenapine exposure Details Enasidenib Atogepant Qulipta Altered atogepant exposure Details Enasidenib Cariprazine Vraylar Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Enasidenib Amlodipine Amvaz® Reduced amLODIPine exposure Details Enasidenib Axitinib Inlyta Altered (increased/reduced) axitinib exposure and an increased risk of axitinib-related adverse effects or reduced efficacy of axi... Details Enasidenib Bosutinib Bosulif Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Enasidenib Brigatinib Alunbrig Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Enasidenib Clindamycin Injection ANTIROBE Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Enasidenib Clindamycin Topical C/T/S® Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Enasidenib Clindamycin Vaginal Cleocin Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Enasidenib Cobimetinib Cotellic Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Enasidenib Cyclosporine Injection Atopica Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Enasidenib Cyclosporine Ophthalmic Cequa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Enasidenib Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Enasidenib Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Enasidenib Dasatinib Phyrago Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Enasidenib Dihydroergotamine Injection DHE-45® Injection Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Enasidenib Dihydroergotamine Nasal Spray Migranal Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Enasidenib Docetaxel Beizray Altered (increased/reduced) DOCEtaxel exposure and an increased risk of DOCEtaxel-related adverse effects or reduced efficacy of D... Details